Literature DB >> 10410920

Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma.

K Malmström1, R Sorva, M Silvasti.   

Abstract

With powder inhalers, optimal performance is dependent on the inspiratory flow produced by the patient through the devices. The objective of this open, non-randomized study was to evaluate the suitability of a new, multidose, dry powder inhaler, the Easyhaler, for children with asthma. The peak inspiratory flow (PIF) through the Easyhaler (PIF(EH)) was measured with a pneumotachograph in 120 asthmatic children aged 4-16 yr. The bronchodilatory effect of 0.2 mg salbutamol through the Easyhaler was compared with that of 0.2 mg salbutamol through a metered dose inhaler (MDI) with a spacer, in 15 children with obstruction. The mean PIF(EH) was 56 l/min (range 22-83 l/min). The PIF(EH) correlated significantly with age, height, and absolute peak expiratory flow (PEF), but not with the level of obstruction (PEF percentage of predicted, range 45-146%). Only four children (aged 5, 6, 10, and 16 yr) had PIF(EH) values below 28 l/min, which has been shown in in vitro studies to be the threshold for effective use of the Easyhaler. In 15 children with PEF, < 85% of predicted bronchodilatory effects of 0.2 mg salbutamol through the Easyhaler and from an MDI-cum-spacer were equal. Most children aged 6-16 yr produce PIF values sufficient for the use of the Easyhaler. The gain of 0.2 mg salbutamol from the Easyhaler was equal to that from a new, unprimed, MDI with a spacer in children with asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10410920     DOI: 10.1034/j.1399-3038.1999.101002.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  5 in total

1.  Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.

Authors:  Satu Lähelmä; Merja Kirjavainen; Marjo Kela; Jukka Herttuainen; Mikko Vahteristo; Matti Silvasti; Marjut Ranki-Pesonen
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 2.  Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler.

Authors:  Henry Chrystyn
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

4.  Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials.

Authors:  L Pekka Malmberg; Anna S Pelkonen; Ville Vartiainen; Mikko Vahteristo; Satu Lähelmä; Rain Jõgi
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 3.005

5.  Switching patients from other inhaled corticosteroid devices to the Easyhaler(®): historical, matched-cohort study of real-life asthma patients.

Authors:  David Price; Vicky Thomas; Julie von Ziegenweidt; Shuna Gould; Catherine Hutton; Christine King
Journal:  J Asthma Allergy       Date:  2014-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.